CLINICAL_TRIALS
trial_result
· 2022-12-05
Clinical Trial Update: The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease [Phase 2]
Summary
Phase 2 study evaluating lixivaptan for autosomal dominant polycystic kidney disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Palladio Biosciences | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-12-05